DIFFERENTIAL INHIBITION OF PROSTACYCLIN PRODUCTION AND PLATELET AGGREGATION BY ASPIRIN

The Lancet

Volumn 314, Issue 8154, 1979, Pages 1213-1216

  Masotti, G ^a,b   Poggesi, L ^a,b   Galanti, G ^a,b   Abbate, R ^a,b   Neri Serneri, G G ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; MALONALDEHYDE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE;

BLOOD AND HEMOPOIETIC SYSTEM; BLOOD VESSEL WALL; DOSE RESPONSE; DRUG RESPONSE; HUMAN CELL; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; ASPIRIN; BLOOD PLATELETS; BLOOD VESSELS; CYCLOOXYGENASE INHIBITORS; DEPRESSION, CHEMICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; FEMALE; HUMANS; MALE; MALONDIALDEHYDE; PLATELET AGGREGATION; PROSTAGLANDINS;

EID: 0018575115     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(79)92334-1     Document Type: Article

References (19)

1. Acetylation of prostaglandin synthetase by aspirin
2. The mechanism of the effect of aspirin in human platelets
3. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation
4. Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides
5. Human arterial and venous tissues generate prostacyclin (prostaglandin X) a potent inhibitor of platelet aggregation
6. The use of isolated organs for detecting active substances in the circulating blood
7. A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle stimulating-substance
8. Bioassay by cascade superfusion using a highly sensitive laminar flow technique
9. Studies on lipid peroxides in platelets. I. Method of assay and effect storage
10. Inhibition of platelet aggregation by acetylsalicylic acid on other inhibitors
11. Platelet function studies in human beings receiving 300 mg of aspirin per day
12. Inhibition of platelet prostaglandin synthetase by oral aspirin
13. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin
14. Comparative evaluation of the inhibitory effects of aspirin like drugs on prostaglandin production by human platelets and synovial tissue
15. Increased coronary sinus prostaglandin E-like material (PGE) during myocardial infarction (MI): beneficial effects of aspirin (ASA)
16. Aspirin: a paradoxical effect on bleeding time
17. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin
18. Why aspirin?